Glutathione derivatives enhance adriamycin cytotoxicity in a human lung adenocarcinoma cell line

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2129-2134

  Nakanishi, Yoichi ^a   Matsuki, Hiroaki ^a   Takayama, Koichi ^a   Yatsunami, Jun ^a   Kawasaki, Masayuki ^a   Abe, Masayoshi ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Adriamycin; Chemosensitivity; Glutathione; Glutathione S transferase; Lung cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE;

ARTICLE; CARCINOMA CELL; CELL LYSATE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE; CELL SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; KINETICS; LUNG NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030861257     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Young RC, Ozols RF and Meyers CE: The anthracycline antineoplastic drugs. N Engl J Med 305: 139-153, 1981.
2. Kramer RA, Zakher J and Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 24: 694-697, 1988.
3. Harris AL and Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1092.
4. Deffie AM, Alam T, Seneviratne C, Beenken S.W, Batra JK, Shea TC, Henner WD and Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and p-glycoprotein in cloned cell lines of adriamycin-sensitive and resistant P338 leukemia. Cancer Res 48:3595-3602, 1988.
5. Wu L, Smythe MS, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR and Shoemaker RH: Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52: 3029-3034, 1992.
6. Peters WHM and Roelofs HMJ: Biochemical characterization of resistance to mitoxantrone and adriamycin in caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res 52: 1886-1890, 1992.
7. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T and Okada K: Factors contributing to adriamycin sensitivity in human xenograft tumors: the relationship between expression of the MDR1, GST-p and topoisomerase II genes and tumor sensitivity to adriamycin. Anticancer Res 12: 241-246, 1992.
8. Lee FYF, Sciandra J and Siemann DW. A study of the mechanism of resistance to adriamycin in vivo. Glutathione metabolism, pglycoprotein expression, and drug transport. Biochem Pharmacol 38: 3697-3705, 1989.
9. Batist G, Tulpule A, Sinha BK, Katki AG, Myers C.E and Cowan KH: Overex pression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
10. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K, Terada M and Tew KD: Glutathione-S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265: 4296-4301, 1990.
11. Schisselbauer JC, Crescimanno M, D'Alessandro N, Clapper M, Toulmond S, Tapiero H and Tew KD: Glutathione, glutathione S-transferases, and related redox enzymes in adriamycin-resistant cell lines with a multidrug resistant phenotype. Cancer Commun 1: 133-139, 1989.
12. Waxman DJ: Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy-a review. Cancer Res 50: 6449-6454, 1990.
13. Kosower N.S and Kosower EM: The glutathione status of cells. Int Rev Cytol 54: 109-160, 1978.
14. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 263: 17205-17208, 1988.
15. Moscow JA, Townsend AJ and Cowan KH: Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GST π gene and its effect on sensitivity to toxins. Mol Pharmacol 36: 022-028, 1989.
16. Cole SPC, Downes HF, Mirski SEL and Clements DJ: Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line. Mol Pharmacol 37: 192-197, 1990.
17. Alaoui-Jamali MA, Panasci L, Centurioni GM, Scheeler R, Lehnert S and Batist G: Nitrogen mustard-DNA interaction in melphalan-resistant glutathione-S-transferase activity. Cancer Chemother Pharmacol 30: 341-347, 1992.
18. Satta T, Isobe K, Yamauchi M, Nakashima I and Takagi H: Expression of MDR1 and glutathione S transferase-π genes and chemosensitivities in human gastrointestinal cancer. Cancer 69: 941-946, 1992.
19. Whelan RDM, Hosking LK, Townsend AJ, Cowan KH and Hill BT: Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. Cancer Commun 1: 359-365, 1989.
20. Bai F, Nakanishi Y, Kawasaki M, Takayama K, Yatsunami J, Pei XH, Tsuruta N, Wakamatsu K and Hara N: Immunohistochemical expression of glutathione S-transferase-π can predict chemotherapy response in patients with non-small cell lung carcinoma. Cancer 78: 416-421, 1996.
21. Rosenberg MC, Colvin OM, Griffith OW, Bigner SH, Elion GB, Horton JK, Lilley E, Bigner DD and Friedman HS: Establishment of a melphalanresistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximinemediated glutathione depletion. Cancer Res 49: 6917-6922, 1989.
22. Meijer C, Mulder NH, Hospers GAP, Uges DRA and de Vries EGE: The role of glutathione in resistance to cisplatin in a human small cell lung cancer 16 cell line. Br J Cancer 62: 72-77, 1990.
23. Armstrong DK, Gordon GB, Hilton J, Streeper RT, Colvin OM and Davidson NE: Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. Cancer Res 52: 1416-1421, 1992.
24. Britten A, Green JA, Broughton C, Browning PGW, White R and Warenius HM: The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells. Biochem Pharmacol 41: 647-649, 1991.
25. Batist G, Schecter R, Woo A, Greene D and Lehnert S: Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol 41: 631-635, 1991.
26. Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D and Hamilton TC: Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36: 147-153, 1987.
27. Medh RD, Gupta V and Awasthi, YC: Reversal of melphalan resistance in vivo and by modulation of glutathione metabolism. Biochem Pharmacol 42: 439-441, 1991.
28. Habib A and Maclouf J: Comparison of leukotriene A4 metabolism into leukotriene C4 by human platelets and endothelial cell. Arch Biochem Biophys 298: 544-552, 1992.
29. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 27: 502-522, 1969.
30. Habig WH and Jakoby WB: Assays for differentiation of glutathione Stransferases. Method Enzymol 77: 398-405, 1981.
31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
32. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E and Minna JD: Chemosensitivity test of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540-547, 1985.
33. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abbott BJ: Protocol for screening chemical agents and natural products against animal tumor and other biochemical systems. Cancer Chemother Rep. Part III 3: 1-103, 1972.
34. Nair S, Singh SV, Samy TSA and Krishan A: Anthracycline resistance in murine leukemic P388 cells. Role of drug efflux and glutathione related enzymes. Biochem Pharmocol 39: 723-728, 1990.
35. Carmichael J, Mitchell JB, Friedman N, Gazdar AF and Russo A: Glutathione and related enzyme activity in human lung cancer cell lines. Br J Cancer 58: 437-440, 1988.
36. Xu BH and Singh SV: Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res 52: 6666-6670, 1992.
37. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL and Ozols RF: Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 6059-6065, 1991.
38. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and Springs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J Clin Oncol 12: 194-205, 1994.